Introduction

Many diseases are being treated with drugs having protein nature. These exogenous proteins having therapeutic role are used as a replacement therapy for self-proteins. These Protein therapeutics are checked and analyzed to maintain biosafety measures and toxicity, viral and bacterial contaminations are removed. Beyond checking these measure there is immune response to a protein drug that is called "immunogenicity" can neutralize the effect of therapeutic proteins and make them useless. There are many factors responsible for causing and effecting immunogenicity including dosage, route of administration, genetic status, and polymorphism and Allergic responses. The body’s first immune response against recombinant therapeutic cytokines is mediated by innate system, subsequently activating the adaptive immune system. The key factors in immunogenicity are the glycosylation and aggregated structure of therapeutic protein that distinguishes the protein/cytokine from self-proteins. There are many ways to reduce immunogenicity like to decrease the number of epitopes for T-cells or by screening the history of allergies. IFNs are basically proteins in nature many of which are related both in 3D structure and amino acid sequences. Recombinant Interferons are widely used these days against viral infections and cancers. In this review the antiproliferative activity and the effects of various recombinant human interferons on the cytotoxic and cytostatic activity of natural killer cells and monocytes are discussed in detail.
resulted due to the absence of the endogenous protein. But immunogenicity can be observed in some patients who already have endogenous proteins. It means other than T and B cell tolerance there are some factors are involved.

**Figure 1:** Immunogenicity of therapeutic cytokines (Moussa and others [7]).

- a. Dose of the therapeutic recombinant cytokine or protein because every protein or drug should be administered in an appropriate amount otherwise high or low amount can cause immunogenicity (Bee and others [8]; Bellomi and others [9]).

- b. Immunologic conditions status of the Patient like if a patient’s immune system is suppressed then there will be less chance of immunogenicity as compared to healthy individual (Jullien and others [6]; Ragnhammar and others [10])

- c. Age of the Patient matters a lot like older individual’s immune system is not as activated as an adult so there will be less chance of immunogenicity (Baker and others [3]).

- d. Prior allergy or sensitization to that therapeutic product or related product results in antibodies production that’s why when these products are administered results in early immunogenic reactions (Jullien and others [6]).

- e. Route of administration also effects immunogenicity like intradermal, subcutaneous, and inhalational routes are considered highly immunogenic as compared to intramuscular and intravenous (IV) routes. The intravenous route is least responsible for immune response (Rosenberg and Worobec [11]).

- f. Genetic condition like HLA of the patient can play a major role in causing immunogenicity (Hoffmann and others [11]).

- g. Recombinant therapeutic protein is human or non-human determine immunogenicity like foreign proteins have more chances of causing immunogenicity as compared to proteins derived from endogenous proteins (Kessler and Ortel [13]). But due to polymorphism these proteins can also immunogenicity (Viel and others [14]).

- h. Glycosylation reduces protein immunogenicity by covering its immunogenic epitopes and reduces protein aggregation (Cole and others [15]; Viel and others [14]).

- i. Storing conditions of the drug like if stored in abnormal conditions then oxidation, reduction, methylation or related damage to the protein can result in immunogenicity (Cleland and others [16]; Morris and others [17]; Wakankar and Borchardt [18]). Potential cytokines, their immunogenic factor and subsequent responses are tabulated in Table 1.

| Serial number | Factors                  | Responses                          | References                          |
|---------------|--------------------------|------------------------------------|-------------------------------------|
| 1             | Cytokine dosage          | Increased immunogenicity           | (Bee and others 2009; Bellomi and others 2003) |
| 2             | Immune status            | Suppressed immunity=Increased immunogenic reactions | (Jullien and others 2015; Ragnhammar and others 1994) |
| 3             | Age                      | Older age=Decreased immunogenicity  | (Baker and others 2010)             |
| 4             | Sensitization            | Early immunogenic reactions        | (Jullien and others 2015)           |
| 5             | Route of Administration  |                                    |                                     |
Response of body’s immunity against protein therapeutics

The first line of defense against protein therapeutics mostly recombinant cytokines involve innate receptor activation with subsequent activation of APCs (antigen presenting cells) e.g. B-cells and dendritic cells (Diebold [19]; Vos and others [20]; Varovinsky and others [21]). These innate receptors present on APCs will in turn activate the adaptive immune response (Adams and others [22]; Medzhitov and Janeway [23]). It has been shown that various functional groups present on drug therapeutics could stimulate the immune system for providing immunogenicity e.g. glycosylation of drugs (Hou and others [24]). This glycosylation make a drug therapeutic unlike ‘self’ and as a result immune system gets activated against it (De Groot and Scott [25]). The following figure illustrates the activation of adaptive immunity; It has been shown that the protein therapeutics/ cytokines that are aggregated or multimeric in nature shows enhanced immunogenicity as they can enhance humoral immunity more efficiently. It has also been shown that therapeutic recombinant cytokine IFN-α could aggregate in transgenic mice and could raise specific antibodies (Bachmann and others [26]; Braun and others [27]; Rosenberg [28]).

Sometimes, antibodies could preexist in the body derived from the endogenous parts of a therapeutic protein i.e. recombinant cytokine. These occur when the auto reactivity of T/B cells is not screened against the self-proteins. Also, the difference in the protein sequence (cytokine) of natural and recombinant proteins could impart the immunogenicity differently (De Groot and Scott [25]; Marshall and others [29]; Reding and others [30]; Reding and others [31]; Rosenberg [28]). The route of administration influences the immunogenicity of a therapeutic cytokine. Intracellular administrations elicit enhanced immunogenic response as compared to sub cutaneous (Schellekens [32]). In case of sub cutaneous administration, dendritic cells in epidermis also called as Langerhans cells acts as APC and phagocytize the protein and after that process of antigen presentation pathway takes place (De Groot and Scott [25]; De Smedt and others [33]; Pritchard and Smith [34]; Sparwasser and others [35]).

In case of administered cytokines (mostly intracellular), the first line of defense is MZ (marginal zone) B cells as they are strategically placed in the marginal zone of lymph nodes and spleen (Sauerborn and others [36]). The figure below illustrates the mechanism of immune response activation against recombinant therapeutic cytokines. Apart from these general mechanisms, there are many underlying factors that influences the immunogenicity against recombinant therapeutic cytokines, that remains largely unknown (Hermeling and others [37]).

Ways to reduce immunogenicity

There are many ways to reduce immunogenicity of the therapeutic cytokine or protein is to decrease the number of epitopes for T-cells. This is done by deimmunization and by doing this procedure immunogenicity can be decreased to a great extent (Bakker and others [31]). The other way to reduce immunogenicity is to screen the history of allergies of the patient because if he is allergic to that therapeutic protein or related one then immunogenicity will enhance. To select the appropriate route of administration and change it during treatment according to the result will prove effective. Third way is to already check the number or quantity of antibodies in the patient for that therapeutic cytokine. Evaluation of the polymorphism for that protein can be proved very effective as it mismatches or similar to therapeutic recombinant cytokine. It is important to remove all the normal cell related impurities. Protein should be glycosylated as it decreases immunogenicity and storage conditions of the drug should be very maintained and appropriate so that denaturation can’t occur (Galsky and others [38]; Pandit-Taskar and others [39]; Vallabhaprasa and others [40]).

Immunogenicity of therapeutic recombinant Interferons

Interferons were first discovered as powerful antiviral agents some 59 years ago. The recombinant IFN-α2a and IFN-α2b first got approval for the treatment of hairy cell leukemia some 30 years ago. Currently these IFNs are used widely for the treatment of viral infections and various types of cancers. IFNs are basically proteins in nature many of which are related both in 3D structure and amino acid sequences. IFNs are categorized into two types; Type I which usually consist of IFN-α, β and ω. While as Type II includes INF-Y which are basically produced by activated T-cells and Natural killer cells. On the other hand, IFN-α and ω are produced by leukocytes while IFN-β are the products of fibroblast (Pfeffer and others [41]) Figure 2.
Recombinant Interferons are widely used these days against viral infections. In one such study recombinant human interferon-α-consensus (IFN-Con1) showed greater antiproliferative activity and enhanced natural killer cell killing of target cells than that of IFN-α2a and IFN-α2b but the antiviral activities of IFN-Con1 were similar to that of IFN-α2a and IFN-α2b. So IFN-Con1 would be significant in low protein concentration than other IFNs for clinical applications. Another study shows that IFN-Con1 as compared to IFN-α is a lower inducer of IL-1β. When three recombinant human interferons naming IFN-α2a, IFN-β and INF-Y were compared in human cultured fibroblast cells against cardiotrophic enterovirus. After few days when a persistent infection was developed IFNs were added. As a result IFN-β and INF-Y showed higher activity and reduced viral load significantly on the contrary IFN-α2a was found to be less effective than the other two interferons. In another research natural IFN-α reduced same amount of viral load at lower concentration as compared to recombinant IFN-α2a (Heim and others [45]).

When the effect of recombinant human leukocyte interferon (IFLa) on the cytotoxic and cytostatic activity of natural killer cells and monocytes was studied it was found that a very small amount of interferon resulted in high natural killing and monocyte-mediated activity. In a study on cancer patients when a single dose of IFN-αrA was injected into cancer patients the cytotoxicity of natural killer cells of all patients declined significantly (Lotzová and others [47]).

In a research it was found that there is a selective antiproliferative effect of recombinant human interferons on malignant human myeloid progenitor cells as compared to normal cells (Grant and others [48]; Ortaldo and others [49]). In another such study it was revealed that, in addition to antiviral activity the recombinant human leukocyte interferons produced in E.coli also exhibit antiproliferative activities (Defrance and others [50]; Evinger and others [51]). In a study it was illustrated that recombinant human interferon-gamma act as a B-cell growth factor (BCGF) but this proliferation of B-cell is short lasting as compared to the proliferation induced by recombinant IL-2 (Defrance and others [50]; Romagnani and others [52]). PCSK6 aid in the cell proliferation, migration, and inflammation in rheumatoid arthritis fibroblast like synoviocytes (RAFS) by activating NF-kB, STAT3 and ERK1/2 signaling pathways (Jiang and others [53]).

As the focus of this article, interferon should be taken into consideration as they are promising for the future. Currently, interferons are being used in viral defense as they generate antiviral state especially against HBV and HCV infections but many studies indicated its adverse effects. For example interferon could induce the
proliferation of pro-inflammatory cytokines like TNF and interleukins which could alter the mechanism and actions of many important metabolic precursors including tryptophan, serotonin etc. The immunogenicity and inflammation also links with depression as serotonin levels are disturbed, many patients have been shown to develop depression (Fried [54]).

It has been observed that aggregated or partially denatured repeated injections of recombinant IFNs, causes decrease in the immune tolerance to self-antigens leads to the to the production of antidrug antibodies (De Santi and others [55]). ADAs cause neutralization of the drug, immune complex disease, allergic reactions and severe autoimmune reactions. IFNs can cause damage by promoting tumor growth because it has observed that IFNg causes resistance to NK cells that results in enhanced metastatic ability and up-regulation of non classical MHC class I molecules that cause inhibition of NK and T cell killing so the assessment of immunogenicity before giving interferon is very necessary [56] Figure 4.

Figure 4: Ways to reduce immunogenicity.

Future perspective

a. Numerous cytokines like TGF-β, CCN2, IFN-α and IFN-β had a great potential for the treatment of connective tissue diseases like Systemic sclerosis (SSc).

b. Recombinant IL-7 has potential role in Tumor-direct Immunotherapy and as an Immunorestorative.

c. TGF-β is predicted to have a great role in engineered organogenesis.

d. Recombinant cytokines will be the key components of future HIV therapies.

e. As interferon shows to be producing adverse effects in patients usually inflammation so restricting the dose of interferon or using interferon in a combination therapy may prevent inflammatory problems associated with the cytokines.

f. Assessment of immunogenicity before giving interferon is very necessary.

References

1. Barandun S, Kistler P, Jeunet F, Isliker H (1962) Intravenous Administration of Human γ-Globulin. Vox Sang 7(2): 157-174.

2. Dasgupta S, Bayry J, André S, Dimitrov JD, Kaveri SV, et al. (2008) auditing protein therapeutics management by professional APCs: toward prevention of immune responses against therapeutic proteins. J Immunol 181(3): 1609-1615.

3. Baker M, Reynolds HM, Lumicisi B, Bryson DJ (2010) Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self/nonself 1(4): 314-322.

4. Casadevall N (2003) Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 18(suppl_8): viii37-viii41.

5. Cassinotti A, Ardizzone S, Porro GB (2008) Adalimumab for the treatment of Crohn’s disease. Biologies 2(4): 763-777.

6. Jullien D, Prinz JC, Nestle FO (2015) Immunogenicity of biotherapy used in psoriasis: the science behind the scenes. The Journal of Investigative Dermatology 135(1): 31-38.

7. Moussa EM, Panchal JR, Moorthy BS, Blum JS, Joubert MK (2016) Immunogenicity of therapeutic protein aggregates. Journal of Pharmaceutical Sciences 105(2): 417-430.

8. Bee JS, Nelson SA, Freund F, Carpenter JE, Randolph TW (2009) Precipitation of a monoclonal antibody by soluble tungsten. J Pharm Sci 98(9): 3290-3301.

9. Bellomi F, Scagnolari C, Tomassini V, Gasperini C, Paolillo A, et al. (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215(1-2): 3-8.

10. Ragnhamar P, Friesen HJ, Frodin JE, Lefvert AK, Hassan M, et al. (1994) Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 84(12): 4078-4087.

11. Rosenberg AS, Worobec A (2004) A risk-based approach to immunogenicity concerns of therapeutic protein products, part I. Biopharm international 17(11): 22-26.

12. Hoffmann S, Cepok S, Grummel V, Lehmann Horn K, Hackermueler J, et al. (2008) HLA-DRB1*0401 and HLA-DRB 0408 Are Strongly Associated with the Development of Antibodies against Interferon-β Therapy in Multiple Sclerosis. The American Journal of Human Genetics 83(2): 219-227.

13. Kessler CM, Ortel TL (2009) Recent developments in topical thrombins. Thrombosis and Haemostasis 102(1): 15-24.
14. Viel KR, Ameri A, Abshire TC, Iyer RV, Watts RG, et al. (2009) Inhibitors of factor VIII in black patients with hemophilia. New England Journal of Medicine 360(16): 1618-1627.

15. Cole KS, Steckbeck JD, Rowles JL, Desrosiers RC, Montelaro RC (2004) Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gpl20 results in redirection of B-cell responses to V3. J Virol 78(3): 1525-1539.

16. Cellden J, Powell MF, Shire S (1993) The development of stable protein formulations: a close look at protein formulation, ademimation, and oxidation. Crit Rev Ther Drug Carrier Syst 10(4): 307-377.

17. Morris MJ, Divgi CR, Pandit Taskar N, Batrakli M, Warren N, et al. (2005) Plot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clinical cancer research 11(20): 7454-7461.

18. Wankar AA, Borchardt RT (2006) Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. Journal of pharmaceutical sciences 95(11): 2321-2336.

19. Diebold SS (2009) Activation of dendritic cells by toll-like receptors and C-type lectins. Handb Exp Pharmacol (188): 3-30.

20. Vos Q, Lees A, Wu QZ, Snapper CM, Mond J (2000) B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunological reviews 176: 154-170.

21. Yarovinsky F, Zhang D, Andersen JR, Bammenberg GL, Serhan CN, et al. (2005) TLRR1 activation of dendritic cells by a protozoan profilin-like protein. Science 308(5728): 1626-1629.

22. Adams EW, Ratner DM, Seeberger PH, Hacohen N (2008) Carbohydrate-Mediated Targeting of Antigen to Dendritic Cells Leads to Enhanced Presentation of Antigen to T Cells. Chembiochem 9(2): 294-303.

23. Medzhitov R, Janeway CA (1997) Innate immunity: impact on the adaptive immune response. Current opinion in immunology 9(1): 4-9.

24. Hou B, Reizis B, DeFranco AL (2008) Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and-extrinsic mechanisms. Immunity 29(2): 272-282.

25. De Groot AS, Scott DW (2007) Immuneogenicity of protein therapeutics. Trends Immunol 28(11): 482-490.

26. Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, et al. (1993) The influence of antigen organization on B cell responsiveness. Science 262(5150): 1440-1451.

27. Braun A, Kwee L, Labow MA, Alsenz J (1997) Protein aggregates seem to play a key role among the parameters influencing the antigenicity of therapeutic proteins. Nephrology Dialysis Transplantation 20(suppl 6): vi3-vi9.

33. De Smidt T, Pajak B, Muraille E, Lespagnard L, Heinen E, et al. (1996) Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 184(4): 1413-1424.

34. Pritchard NR, Smith KG (2003) B cell inhibitory receptors and autoimmunity. Immunology 108(3): 263-273.

35. Sparwasser T, Koch ES, Vahulas RM, Heeg K, Lipford GB, et al. (1999) Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. European journal of immunology 28(6): 2045-2054.

36. Sauerborn M, Brinks V, Jekkoot W, Schellekens H (2010) Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends in pharmacological sciences 31(2): 53-59.

37. Hermeling S, Crommelin DJ, Schellekens H, Jekkoot W (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharmaceutical research 21(6): 897-903.

38. Galsky MD, Eisenberger M, Moore Cooper S, Kelly WK, Slovín SF, et al. (2008) Phase I Trial of the Prostate-Specific Membrane Antigen-Directed Immunocytotoxic MLNZ704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology 26(13): 2147-2154.

39. Pandit Taskar N, O Donoghue JA, Morris MJ, Wills EA, Schwartz LH, et al. (2006) Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-labeled J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. Journal of Nuclear Medicine 49(7): 1066-1074.

40. Vallabhajosula S, Goldsmit J, Kostakoglu L, Milowsky MI, Nauze DM, et al. (2005) Radioimmunotherapy of prostate cancer using 90Yand 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clinical cancer research 11(19): 7159-7205.

41. Pfeiffer LM, Dinarello CA, Herberman RB, Williams BR, Borden EC, et al. (1998) Biological properties of recombinant α-interferons: 40th anniversary of the discovery of interferons. Cancer research 58(12): 2489-2499.

42. Ozes On, Reiter Z, Klein S, Blatt LM, Taylor Mw (1992) A comparison of interferon-Con1 with natural recombinant interferon-α: antiviral, antiproliferative, and natural killer-inducing activities. Journal of interferon research 12(1): 55-59.

43. Blatt LM, Davis JM, Klein SB, Taylor MW (1996) The biologic activity and molecular characterization of novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 16(7): 489-499.

44. Heim A, Stille Siegener M, Pring Äkerblom P, Grumbach I, Brehm C, et al. (1998) Recombinant interferons β and γ have a higher antiviral activity than interferon-α. J Interferon Cytokine Res 18(1): 81-86.

45. Heremans T, Stille Siegener M, Pring Äkerblom P, Grumbach I, Brehm C, et al. (1998) Recombinant interferons β and γ have a higher antiviral activity than interferon-α. J Interferon Cytokine Res 18(1): 81-86.

46. Heim A, Brehm C, Stille Siegener M, Pring Äkerblom P, Grumbach I, Brehm C, et al. (1998) Recombinant interferons β and γ have a higher antiviral activity than interferon-α. J Interferon Cytokine Res 18(1): 81-86.

47. Lotzová E, Savary CA, Quesada JR, Gutterman JU, Hersh EM (1983) Effect of human recombinant interferon on cytotoxic activity of natural killer cells. Cellular immunology 71(5): 903-910.

48. Grant S and Bhalia K, Weinseid IB, Pestka S, Fisher PB (1982) Differential effect of recombinant human leukocyte interferon on human leukemic and normal myeloid progenitor cells. Biochemical and biophysical research communications 108(3): 1048-1055.
49. Ortaldo J, Mason A, Reiher E, Moschera J, Kelder B, et al. (1983) Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. Journal of Biological Chemistry 258(24): 15011-15015.

50. Defrance T, Aubry J, Vanervliet B, Banchereau J (1986) Human interferon-gamma acts as a B cell growth factor in the anti-IgM antibody co-stimulatory assay but has no direct B cell differentiation activity. J Immunol 137(12): 3861-3867.

51. Evinger M, Maeda S, Pestka S (1981) Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. J Biol Chem 256(5): 2113-2114.

52. Romagnani S, Giudizi M, Bigiotti R, Almerigogna F, Mingari C (1986) B cell growth factor activity of interferon-γ. Recombinant human interferon-γ promotes proliferation of anti-μ-activated human B lymphocytes. Journal of Immunology 136(10): 3513-3516.

53. Jiang H, Wang L, Wang F, Pan J (2017) Proprotein convertase subtilisin/kexin type 6 promotes in vitro proliferation, migration and inflammatory cytokine secretion of synovial fibroblast like cells from rheumatoid arthritis via nuclear factor κB, signal transducer and activator of transcription 3 and extracellular signal regulated 1/2 pathways. Molecular Medicine Reports 16(6): 8477-8484.

54. Fried MW (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36(S Suppl 1): S237-44.

55. De Santi L, Costantini M, Anunziata P (2005) Long time interval between multiple sclerosis onset and occurrence of primary Sjögren’s syndrome in a woman treated with interferon-beta. Acta Neurol Scand 112(3): 194-196.

56. Reding M, Wu H, Knopf M, Okita D, Diethelm Okita B, et al. (1999) CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thrombosis and haemostasis 82(2): 509-515.

57. Ortaldo J, Mason A, Reiher E, Moschera J, Kelder B, et al. (1983) Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells. Journal of Biological Chemistry 258(24): 15011-15015.